Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Anteris Technologies Global Corp. (AVR) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D Neutral Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Middle 30% of 5172 stocks scored
Rank correlation · 90D -14.0% Spearman, 211 dates
Market Cap $590M small-cap · #10 of 27 peers
Summary

Anteris Technologies Global Corp. (AVR) stock forecast summary

On Oct. 16, 2026, AVR is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.

Anteris Technologies Global Corp. is a small-cap company with a market capitalization of $590M. It ranks number 10 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast. Its D/E Ratio of 0.08x is the lowest of the 24 peers that report one.

For AVR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 211 forecast dates between 2025-05-16 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 254 forecast dates between 2025-05-16 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, AVR included.

Follow AVR free
Price

AVR price chart and AI forecast

AVR
Cross-section · 2026-10-16

How AVR ranks among 5172 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Anteris Technologies Global Corp. (AVR) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.

Valuation & Market

MetricAVRIndustry medianRank
Market Cap $590M $76M 10/27
P/B Ratio 2.35x 2.28x 11/22
EPS $-2.27 – –
Book Value/Share $2.58 – –
Revenue/Share $0.02 – –
FCF/Share $-0.91 – –

Profitability & Margins

MetricAVRIndustry medianRank
ROIC -41.8% -5.7% 15/22
Operating Margin -6077.5% -8.7% 20/21
EBT Margin -5859.0% -19.3% 20/21
Tax Rate -0.5% – –

Financial Health

MetricAVRIndustry medianRank
Current Ratio 14.20x 2.57x 2/25
Quick Ratio 14.20x 1.89x 1/22
D/E Ratio 0.08x 0.71x 24/24
Financial Leverage 1.08x 1.71x 24/24
Interest Coverage -298.1x -3.4x 17/21
Working Capital $242M $51M 8/25

Cash Flow

MetricAVRIndustry medianRank
Operating Cash Flow -$86M -$690K 25/25
Free Cash Flow -$88M $2M 16/16
Capital Spending -$2M -$2M 8/16
FCF/Sales -5046.3% 1.2% 16/16
CapEx/Sales 111.8% 1.3% 1/16

Operational Efficiency

MetricAVRIndustry medianRank
Asset Turnover 0.01x 0.72x 18/18
Receivables Turnover 3.2x 5.6x 16/17
Inventory Turnover 70.1x 2.1x 1/22
Fixed Assets Turnover 0.3x 5.5x 18/19
Days Sales Outstanding 114 days 65 days 2/17
Days Inventory 5 days 171 days 22/22
Payables Period 3318 days 55 days 2/19
Cash Conversion Cycle -3198 days 140 days 14/15

Income Statement

MetricAVRIndustry medianRank
Total Revenue $2M $110M 17/19
Operating Income -$106M -$6M 24/25
R&D Expense $77M $20M 7/22
SG&A Expense $31M $126M 15/22
Cost of Goods Sold $560K $55M 21/22

Dividend & Shareholder Information

MetricAVRIndustry medianRank
Shares Outstanding 97M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$261M95.9% of assets
Cash & Short-term Investments$250M92.0% of assets
Accounts Receivable$550K0.2% of assets
Inventory$10K0.0% of assets
Total Liabilities$21M7.7% of assets
Short-term Debt$13M4.9% of assets
Quarterly Financial Reports

AVR quarterly financials and insider trading

Industry Peers · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Anteris Technologies Global Corp. (AVR) industry peers

Companies classified under the same SEC industry code as Anteris Technologies Global Corp. (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
AVR Anteris Technologies Global Corp. ▶ $590M – 2.4x
ISRG Intuitive Surgical Inc ▼ $150.74B 49.0x 8.3x
STE Steris Plc ▼ $21.71B 28.8x 3.0x
ZBH Zimmer Biomet Holdings, Inc. ▼ $18.12B 18.9x 1.4x
SNN Smith & Nephew Plc ▼ $12.75B 16.7x –
ALGN Align Technology Inc ▶ $10.46B 25.7x 2.5x
MSA Msa Safety Inc ▼ $6.91B 22.2x 4.9x
ESTA Establishment Labs Holdings Inc. ▲ $1.76B – 81.6x
ENOV Enovis Corp ▶ $1.13B – 0.8x
CDRE Cadre Holdings, Inc. ▼ $1.13B 26.9x 3.3x
SMTI Sanara Medtech Inc. ▼ $305M – 38.4x
INGN Inogen Inc ▲ $166M – 1.0x
LAKE Lakeland Industries Inc ▲ $90M – 0.7x
NTRB Nutriband Inc. ▲ $76M – 14.3x
APT Alpha Pro Tech Ltd ▲ $57M 14.2x 0.9x
COCH Envoy Medical, Inc. ▼ $52M – –
MYO Myomo, Inc. ▲ $48M – 8.2x
MLSS Milestone Scientific Inc. ▲ $29M – 8.4x
LFWD Lifeward Ltd. ▲ $17M – 1.4x
CUPR Cuprina Holdings (Cayman) Ltd ▶ $13M – –
UEEC United Health Products, Inc. ▲ $12M 4.7x –
RGNT Regentis Biomaterials Ltd. ▶ $10M – 2.2x
CLGN Collplant Biotechnologies Ltd ▶ $7M – 1.1x
LGMK Logicmark, Inc. ▲ $1M – 0.1x
BBLG Bone Biologics Corp ▲ $1M – 0.3x
RBOT Vicarious Surgical Inc. ▼ $550K – 0.1x
FEED Envue Medical, Inc. ▼ $340K – –

Where AVR sits on the market map

Industrial Applications and Services · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Explore the map →
News

Anteris Technologies Global Corp. (AVR) stock news

Loading...

FAQ

Anteris Technologies Global Corp. (AVR) stock forecast FAQ

What is the Anteris Technologies Global Corp. (AVR) stock forecast?

On Oct. 16, 2026, AVR is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.

How accurate are Anteris Technologies Global Corp. stock predictions?

For AVR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 211 forecast dates between 2025-05-16 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 254 forecast dates between 2025-05-16 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Anteris Technologies Global Corp. forecasts updated?

Anteris Technologies Global Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Anteris Technologies Global Corp.'s industry peers?

27 issuers in our coverage, AVR included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.